DCPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DCPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:
We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.
Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
As of today (2024-04-29), Deciphera Pharmaceuticals's share price is $25.28. Deciphera Pharmaceuticals's GF Value is $16.84. Therefore, Deciphera Pharmaceuticals's Price-to-GF-Value for today is 1.50.
Based on the relationship between the current stock price and the GF Value, GuruFocus believes Deciphera Pharmaceuticals is Significantly Overvalued.
Deciphera Pharmaceuticals (NAS:DCPH) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:
Posssible Evaluations | All-in-One Screener Examples (2) |
Possible Value Trap, Think Twice (1) | Predictable Companies that possibly be Value Traps |
Significantly Overvalued | Predictable Companies which are Significantly Overvalued |
Modestly Overvalued | Predictable Companies which are Modestly Overvalued |
Fairly Valued | Predictable High Quality Companies which are Fairly Valued |
Modestly Undervalued (3) | Predictable High Quality Companies which are Modestly Undervalued |
Significantly Undervalued (3) | Predictable High Quality Companies which are Significantly Undervalued |
(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(3) There is only a sufficient margin of safety when the stock is undervalued.
Deciphera Pharmaceuticals's Price-to-GF-Value for today is calculated as
Price-to-GF-Value | = | Share Price | / | GF Value |
= | 25.28 | / | 16.84 | |
= | 1.50 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Jama Pitman | officer: SVP, Regulatory & Quality | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Daniel C. Martin | officer: Chief Commercial Officer | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Thomas Patrick Kelly | officer: Chief Financial Officer | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Matthew L Sherman | officer: EVP & Chief Medical Officer | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Steven L. Hoerter | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Dashyant Dhanak | officer: EVP & Chief Scientific Officer | C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803 |
Daniel Lee Flynn | officer: Chief Scientific Officer | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Franklin Stuart Friedman | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Dennis Leo Walsh | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Brightstar Associates Llc | 10 percent owner | 1020 CENTRAL STREET, KANSAS CITY MO 64105 |
James Arthur Bristol | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Michael Douglas Taylor | director, officer: See Remarks | C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451 |
Patricia L Allen | director | C/O DECIPHERA PHARMACEUTICALS, INC, 200 SMITH STREET, WALTHAM MA 02451 |
Christopher John Morl | officer: Chief Business Officer | C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451 |
Ron Squarer | director | C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066 |
From GuruFocus
By GuruFocus Research • 12-15-2023
By GuruFocus Research • 09-22-2023
By Business Wire Business Wire • 01-24-2023
By GuruFocus Research • 12-02-2023
By Business Wire Business Wire • 04-19-2023
By Business Wire Business Wire • 01-31-2023
By GuruFocus Research • 10-05-2023
By GuruFocus Research • 09-22-2023
By Business Wire • 01-08-2024
By Business Wire • 01-02-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.